Fractyl Health Eyes 2028 Revita Launch for Post-GLP-1 Weight Maintenance
Fractyl Health NASDAQ: GUTS outlined a commercial strategy for its investigational Revita procedure, positioning the one-time endoscopic therapy as a potential option for patients seeking to maintain weight loss after discontinuing GLP-1 medicines.
Insurers Are Pulling Back From GLP-1 Drugs. The FDA Just Handed Eli Lilly Its Best Weapon Yet
Employer coverage of GLP-1 drugs is collapsing heading into 2027, but the FDA just gave Eli Lilly a specific piece of ammunition that could change the conversation in payer meetings for at least one slice of that market.
Jim Cramer: This Little-Talked-About Drug Could Target the “Biggest Market of All Time” Aside From Eli Lilly's GLP-1 Drugs
Jim Cramer is flagging an Amgen drug that Wall Street has largely ignored, and he thinks the cardiovascular opportunity behind it could rival the most valuable pharmaceutical market ever created.
GLP-1 Coverage Fell From 72% to 60%. Is Eli Lilly's Weight-Loss Boom Hitting an Insurance Wall?
Employer insurance coverage for GLP-1 weight-loss drugs is shrinking, yet Eli Lilly just posted a 47% revenue surge. Something underneath the headlines is keeping volumes alive, and it changes how shareholders should read every coverage headline going forward.
Should Value Investors Buy Global Partners (GLP) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Can Eli Lilly's Oncology Portfolio Drive Growth Beyond GLP-1 Drugs?
LLY's oncology revenues rise 11% in the first half of 2026, as newer drugs gain traction and pipeline assets add growth opportunities.
GLP-1 maker hit with 'sell' rating as 2027 revenue cliff fears mount
Novo Nordisk (NYSE:NVO) has received a downgrade from Deutsche Bank, with analysts lowering their target price as midterm growth concerns and pipeline issues mount. The shares dropped 2.52% to DKK 297.25 as the broker adjusted its rating to 'sell', moving down from a previous 'hold' view following the drugmaker's mixed second-quarter update.
Lilly's GLP-1 pill hits UK pharmacies as US battle with Novo intensifies
Eli Lilly's weight-loss and diabetes pill goes on sale in UK pharmacies from Monday, giving patients an oral alternative to the injections that have dominated the market. Foundayo, also known as orforglipron, is available on private prescription after the Medicines and Healthcare products Regulatory Agency approved it earlier this month.
Structure Therapeutics: A Strong Bet For An Oral GLP-1 Approval Before 2030
Structure Therapeutics (GPCR) maintains a Buy rating, driven by strong Phase 2b data for its oral GLP-1 candidate aleniglipron targeting obesity. Aleniglipron demonstrated up to 16.2% weight loss at 44 weeks, a favorable discontinuation rate, and is now in Phase 3 studies with pivotal data expected Q4 2028. GPCR's $1.34bn cash position is expected to fund completion of Phase 3, supporting a runway through key value inflection points despite high R&D burn.
Can Awiqli Help Novo Nordisk Build a New Growth Engine Beyond GLP-1s?
NVO's U.S. launch of Awiqli introduces the first once-weekly basal insulin, potentially giving the company a new growth opportunity beyond its pressured GLP-1 franchise.
Amylyx stock soars on GLP-1 success: here's why investors should sell
Amylyx Pharmaceuticals (AMLX) shares exploded to the upside on August 18th after the company reported blockbuster topline results from its pivotal Phase 3 LUCIDITY trial. The late-stage study evaluated avexitide – the pharmaceutical firm's first-in-class GLP-1 receptor antagonist – in patients suffering from post-bariatric hypoglycemia (PBH).
Is Global Partners (GLP) a Solid Growth Stock? 3 Reasons to Think "Yes"
Global Partners (GLP) could produce exceptional returns because of its solid growth attributes.
